Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) is a fusion protein consisting of ubiquitin at the N terminus and ribosomal protein L40 (eL40) at the C terminus[1][2][4]. This protein is post-translationally processed to release free ubiquitin, which targets cellular proteins for degradation by the 26S proteasome, and to supply the ribosomal protein L40, a component of the large (60S) ribosomal subunit essential for protein synthesis[2][3]. UBA52 is highly conserved across eukaryotes and functions as a housekeeping gene to maintain the basal ubiquitin pool for essential cellular processes, particularly in non-stress conditions[3]. UBA52 deficiency disrupts embryogenesis, cell cycle progression, and protein synthesis, leading to developmental arrest and cell death[1][3]. There is no evidence that UBA52 is directly targeted by drugs or used as a biomarker in clinical practice. However, its fundamental role in cellular homeostasis and development makes it indispensable for organismal viability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52).